PALI News & Events

The major averages finished broadly higher as investors await news out of the Middle East. President Trump said the U.S. and Iran will meet to negotiate after days of strikes as the market shifts focus from geopolitics back toward macro data. Investors are watching labor market releases, including the JOLTS report and Thursday's payroll report, for clues on the Federal Reserve path. Markets continue to weigh a resilient economy against concerns that sticky inflation could keep the Fed more restrictive than expected.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:SpaceXwillon July 7Comcastplans to separate intothrough a tax-free spin-off of NBCUniversal and SkySpaceXand Charterhave discussed partnering on a mobile phone offering,Verizonand BT Groupwilland combine international operationsRocket LabIridiumfor $54 per share in a cash and stock transaction2. WALL STREET CALLS:Robloxto Buy at AreteAdobeto Neutral at Phillip SecuritiesDoximityto Underperform from Buy at BofAQuantinuumwith mostly Buy or equivalent ratings as Wall Street rolled out coverageCoverage of Liftoff Mobilewas alsowith mostly bullish ratings3. AROUND THE WEB:Carlislehas made unsolicited offers for Owens Corning, WSJ reportsEli Lillyand Regeneronare among the first selections for the FDA's PreCheck program, CNBC reportsAmazoncould pay more for Anthropic's technology, The Information reportsIntelis gaining momentum from the AI boom and new partnerships with Nvidia, Apple, and Elon Musk's Terafab project, but its long-term future depends on proving its new 14A manufacturing process can succeed and help restore U.S. chip production, New York Times reportsSamsungand SK Hynix intend to invest over $500B in a new chip-making hub in South Korea, WSJ says4. MOVERS:Repay Holdingsincreases after Forager Fundthe company for $5.25 per shareFuelCellgains after B. Rileythe stock to BuyPalisade Biohigher afterto start its ulcerative colitis studyEvommunelower after Phase 2b trial of EVO756Larimar Therapeuticsfalls afterof its rolling BLA for nomlabofusp5. EARNINGS/GUIDANCE:GameStopprovidedPerfect Moment, with EPS and revenue higher year-over-yearKolibri Global EnergyprovidedNiketoon June 30Constellation Brandstoon June 30INDEXES:The Dow rose 306.63, or 0.59%, to 52,182.74, the Nasdaq gained 522.53, or 2.07%, to 25,820.15, and the S&P 500 advanced 86.41, or 1.18%, to 7,440.43.

The major averages were broadly higher near noon as investors await news out of the Middle East after President Trump said the U.S. and Iran will meet to negotiate after days of strikes. Oil prices are up again amid renewed tensions, though are still well below where they were just weeks ago.The key theme this week is shifting from geopolitics back toward macro data. Investors are watching labor market releases, including the JOLTS report and Thursday's payroll report, for clues on the Federal Reserve path. Markets continue to weigh a resilient economy against concerns that sticky inflation could keep the Fed more restrictive than expected.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:SpaceXwillon July 7Comcastplans to separate intothrough a tax-free spin-off of NBCUniversal and SkySpaceXand Charterhave discussed partnering on a mobile phone offering,Verizonand BT Groupwilland combine international operationsRocket LabIridiumfor $54 per share in a cash and stock transaction2. WALL STREET CALLS:Robloxto Buy at AreteAdobeto Neutral at Phillip SecuritiesDoximityto Underperform from Buy at BofAQuantinuumwith mostly Buy or equivalent ratings as Wall Street rolled out coverageCoverage of Liftoff Mobilewas alsowith mostly bullish ratings3. AROUND THE WEB:Salesforceemployees are concerned that Anthropic's Claude Tag could undermine Slackbot and strengthen Anthropic's influence within the enterprise software market, The Information saysIntelis gaining momentum from the AI boom and new partnerships with Nvidia, Apple, and Elon Musk's Terafab project, but its long-term future depends on proving its new 14A manufacturing process can succeed and help restore U.S. chip production, New York Times reportsSamsungand SK Hynix intend to invest over $500B in a new chip-making hub in South Korea, WSJ saysVolkswagenintends to end its automated driving partnership with Bosch as part of its efforts to cut costs and boost competitiveness, Reuters reportsMetahas imposed strict limits on applied AI staff use of external coding tools like Claude Code and Codex due to concerns about inadvertent model distillation, The Information says4. MOVERS:Repay Holdingsincreases after Forager Fund offered tofor $5.25 per shareFuelCellgains after B. Rileythe stock to BuyPalisade Biohigher afterto start its ulcerative colitis studyEvommunelower after Phase 2b trial ofits primary endpointLarimar Therapeuticsfalls afterof its rolling BLA for nomlabofusp5. EARNINGS/GUIDANCE:GameStopPerfect Moment, with EPS and revenue higher year-over-yearKolibri Global EnergyNikeon June 30Constellation Brandson June 30INDEXES:Near midday, the Dow was up 0.44%, or 230.00, to 52,106.11, the Nasdaq was up 1.34%, or 339.82, to 25,637.44, and the S&P 500 was up 0.75%, or 55.11, to 7,409.13.

Palisade Bio announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for its oral drug candidate, PALI-2108. The clearance allows the company to initiate its global Phase 2 ASCENTRA-UC study evaluating PALI-2108 in patients with moderately to severely active ulcerative colitis. The trial is expected to enroll up to 204 patients across North America and Europe. Palisade expects to begin patient enrollment in the second half of 2026 and report primary efficacy results in the second half of 2027. "FDA clearance of our IND application is a significant milestone for Palisade Bio and an important validation of the extensive preclinical, manufacturing and clinical work completed to advance PALI-2108 into Phase 2 development," said Mitch Jones, president and chief medical officer of Palisade Bio.

Palisade Bio files $300M mixed securities shelf